IO Drugs: Key to the Cancer Moonshot?
7:00am - 8:00am
Checkpoint inhibitor immuno-oncology (IO) treatments, widely considered as one the most promising breakthroughs in drug development, are a focus of the Cancer Moonshot initiative. But are these new therapies getting reimbursed and what are the challenges they face in gaining market access?
Join us for a live webinar to take a data-driven look at the key challenges facing IO drugs including:
– Cost and value
– Interpretation of clinical efficacy evidence
– Restrictions issued by HTA agencies
Contact: Lorraine Versoza
Contact Phone: 323-640-5096
Contact Email: email@example.com